Cargando…

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform

Access to a comprehensive molecular alteration screening is patchy in Europe and quality of the molecular analysis varies. SPECTAlung was created in 2015 as a pan-European screening platform for patients with thoracic malignancies. Here we report the results of almost 4 years of prospective molecula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morfouace, M., Novello, S., Stevovic, A., Dooms, C., Janžič, U., Berghmans, T., Dziadziuszko, R., Gorlia, T., Felip, E., Paz-Ares, L., Mazieres, J., O’Brien, M., Bironzo, P., Vansteenkiste, J., Lacroix, L., Dingemans, A. C., Golfinopoulos, V., Besse, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9117328/ https://www.ncbi.nlm.nih.gov/pubmed/35585228 http://dx.doi.org/10.1038/s41598-022-12056-0

Ejemplares similares

First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN
por: Morfouace, Marie, et al.
Publicado: (2020)

EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
por: de Rojas, Teresa, et al.
Publicado: (2019)

International clinical trials setting for rare cancers: organisational and regulatory constraints—the EORTC perspective
por: Shash, Emad, et al.
Publicado: (2013)

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033
por: Klein, Martin, et al.
Publicado: (2020)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Immune Checkpoint Inhibitors in Patients With Cancer and Infection by Hepatitis B or C Virus: A Perspective Through the Results of a European Survey
por: Tagliamento, Marco, et al.
Publicado: (2022)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

New emerging targets in cancer immunotherapy: the role of VISTA
por: Tagliamento, Marco, et al.
Publicado: (2020)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Local for advanced, is this a paradox?
por: Bungaro, Maristella, et al.
Publicado: (2021)

Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951
por: Idbaih, Ahmed, et al.
Publicado: (2010)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Pujol, Jean-Louis, et al.
Publicado: (2021)

Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran
por: Khoshnevisan, Alireza, et al.
Publicado: (2012)

Development of an item bank for the EORTC Role Functioning Computer Adaptive Test (EORTC RF-CAT)
por: Gamper, Eva-Maria, et al.
Publicado: (2016)

Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13
por: Coon, Cheryl D., et al.
Publicado: (2022)

KRAS oncogene in lung cancer: focus on molecularly driven clinical trials
por: Kempf, Emmanuelle, et al.
Publicado: (2016)

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?—a literature review
por: Leone, Gianmarco, et al.
Publicado: (2020)

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
por: Fosså, S. D., et al.
Publicado: (1995)

Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D
por: Jansen, Femke, et al.
Publicado: (2021)

Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23
por: Hau, Peter, et al.
Publicado: (2021)

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma: A randomized phase III Intergroup study by EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033)
por: Baumert, Brigitta G., et al.
Publicado: (2016)

Validation of a locked nucleic acid based wild-type blocking PCR for the detection of EGFR exon 18/19 mutations
por: Vliegen, Liesbet, et al.
Publicado: (2015)

Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21
por: Friend, E, et al.
Publicado: (2011)

Phase 1–3 of the cross‐cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ‐22
por: Oberguggenberger, Anne Sophie, et al.
Publicado: (2018)

International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26
por: Sztankay, Monika, et al.
Publicado: (2018)

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
por: Bady, Pierre, et al.
Publicado: (2018)

Real-World Experience in Treatment of Patients with Non-Small-Cell Lung Cancer with BRAF or cMET Exon 14 Skipping Mutations
por: Janzic, Urska, et al.
Publicado: (2023)

Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26
por: Holzner, Bernhard, et al.
Publicado: (2012)

Targeting KRAS in NSCLC: Old Failures and New Options for “Non-G12c” Patients
por: Jacobs, Francesca, et al.
Publicado: (2021)

Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer
por: Wolf, J., et al.
Publicado: (2022)

Surgical management of melanoma: an EORTC Melanoma Group survey
por: Testori, A, et al.
Publicado: (2013)

Validation of EORTC IN-PATSAT 32 in Morocco: Methods and Processes
por: Obtel, Majdouline, et al.
Publicado: (2017)

Psychometric properties of the EORTC QLQ-C30 in Uganda
por: Naamala, Allen, et al.
Publicado: (2021)

Assessing measurement invariance in the EORTC QLQ-C30
por: van Roij, Janneke, et al.
Publicado: (2021)

The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30
por: McTaggart-Cowan, Helen, et al.
Publicado: (2019)

German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30
por: Kemmler, Georg, et al.
Publicado: (2019)

A Multinational Pilot Study on Patients’ Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires
por: van Leeuwaarde, Rachel S., et al.
Publicado: (2022)

Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept
por: Berghmans, Thierry, et al.
Publicado: (2020)

Deciphering Lung Adenocarcinoma Heterogeneity: An Overview of Pathological and Clinical Features of Rare Subtypes
por: Mogavero, Andrea, et al.
Publicado: (2023)

Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors
por: Lassman, Andrew B., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ks5ntti0ee5n1mbur45n6a5t9m